コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ficant reduction was observed (P = 0.004) in serum ferritin.
2 y stable within subjects and correlated with serum ferritin.
3 decreased tissue iron stores, as measured by serum ferritin.
4 t consistently was inversely associated with serum ferritin.
5 e ratio of the serum transferrin receptor to serum ferritin.
6 absorbed iron was inversely associated with serum ferritin.
7 es between groups in adjusted mean height or serum ferritin.
8 eral flow immunoassay test strip to quantify serum ferritin.
9 plasma lactate deshydrogenase bilirubin, and serum ferritin.
10 l guidelines recommended a concentration for serum ferritin.
13 .42 g/dL; 95% CI: 0.28, 0.56; P < 0.001) and serum ferritin (1.36 mug/L; 95% CI: 1.23, 1.52; P < 0.00
14 sfusion duration, 15 months, average (+/-SD) serum ferritin 2718 plus or minus 1994 ng/mL, and averag
17 by multi-breath-hold MRI T2* and compared to serum ferritin (a traditional marker of iron overload).
18 n immunodiagnostic platform for detection of serum ferritin, a biomarker for iron deficiency, is pres
19 dietary iron bioavailability.Iron intake and serum ferritin, a quantitative marker of body iron store
22 nts, we measured the inflammatory biomarkers serum ferritin and C-reactive protein (CRP) in 66 patien
23 When patients were stratified based on their serum ferritin and CRP levels, patients with elevation i
24 An inverse relation was observed between serum ferritin and iron absorption from both ferritin an
27 rmed a comprehensive analysis of the role of serum ferritin and its genetic determinants in the patho
30 significant correlation was observed between serum ferritin and liver iron concentration evaluated by
31 ecutive patients with a moderate increase in serum ferritin and liver iron levels who did not carry g
34 Patients with Fpn mutation D157G show high serum ferritin and normal to slightly elevated transferr
35 fter adjusting for the acute-phase response, serum ferritin and RBP concentrations were associated wi
36 iron supplementation significantly improved serum ferritin and serum transferrin receptor (sTfR) con
38 iron stores (TBI), which are calculated from serum ferritin and soluble transferrin receptor concentr
40 fect of iron fortification on hemoglobin and serum ferritin and the prevalence of iron deficiency and
42 ferritin uptake and found that Scara5 bound serum ferritin and then stimulated its endocytosis from
44 nt of body iron based on measurements of the serum ferritin and transferrin receptor was used to exam
45 nts in North America for iron overload using serum ferritin and transferrin saturation measurements a
47 ed iron stores, defined as elevation of both serum ferritin and transferrin-iron saturation (TS), in
49 ber, Shimada histopathologic classification, serum ferritin, and bone marrow immunocytology (sensitiv
50 abnormal values for transferrin saturation, serum ferritin, and erythrocyte protoporphyrin, with the
51 ods results in an improvement in hemoglobin, serum ferritin, and iron nutriture and a reduced risk of
52 ased hemoglobin, transferrin saturation, and serum ferritin, and it significantly reduced serum phosp
56 cteristics, cancer, smoking, alcohol intake, serum ferritin, and serum creatinine, low versus normal
61 me (MCV), serum transferrin saturation (TS), serum ferritin, and white blood cell count of African-Am
66 ths of transfusion (R = 0.795, P <.001), but serum ferritin at biopsy did not correlate with months o
68 mples by the spot method compared with using serum ferritin by the traditional method in a field sett
69 amin A reduced CRP (by 9.6 mg/L; P = 0.011), serum ferritin (by 18.1 microg/L; P = 0.042), and erythr
70 y in women with BMI (in kg/m(2)) >/=18.5 and serum ferritin concentration </=150 mug/L, although low
71 n predefined success criteria for changes in serum ferritin concentration (all patients) and cardiac
73 concentration was correlated positively with serum ferritin concentration and negatively with homozyg
75 tal weight were maternal height, weight, and serum ferritin concentration at booking, but not haemogl
76 ed all six doses of study drug (n = 57), the serum ferritin concentration increased significantly for
77 KI risk with high-dose deferasirox and lower serum ferritin concentration is consistent with overchel
78 on absorption: Ln absorption, % (adjusted to serum ferritin concentration of 30 microg/L) = 1.9786 +
79 e diagnosis of ID, a cutoff of 100 mug/L for serum ferritin concentration should be considered in mos
81 d progressively increasing mean age-adjusted serum ferritin concentration values in each ethnic group
85 ption from meals, and models of iron intake, serum ferritin concentration, and iron requirements.We d
92 The World Health Organization recommends serum ferritin concentrations as the best indicator of i
95 pendent studies show that only patients with serum ferritin concentrations more than 1000 microg/L ar
97 estigate the effects of deferasirox dose and serum ferritin concentrations on kidney function and the
98 s well as adult vegetarians often have lower serum ferritin concentrations than omnivores, which is i
100 akes were 13.6, 10.3, and 10.9 mg/d and mean serum ferritin concentrations were 140.7, 49.4, and 96.7
103 ation Survey (NHANES III), and then the mean serum ferritin concentrations were determined for the tr
105 d portable diagnostics for quantification of serum ferritin concentrations, an iron status biomarker,
107 bin, serum iron, transferrin saturation, and serum ferritin concentrations, on consecutive patients r
112 re treated with either anti-A blood grouping serum, ferritin-conjugated anti-A serum, free ferritin,
118 ith normal transferrin saturations, elevated serum ferritins, elevated red cell protoporphyrin IX lev
119 fects of the intervention on iron status for serum ferritin for participants in Italy (P = 0.04) and
120 bsorption was 36 +/- 19% (range: 4-81%), and serum ferritin (geometric x) was 27 microg/L (range: 4-1
122 rum ferritin levels (77.8% versus 33.3% with serum ferritin > 300 ng/ml; p = 0.006), and diabetes (44
125 s to 10-12 g/dL or normalization (n = 8) and serum ferritin >100 mug/L (n = 7) or 200 mug/L (n = 4).
126 ase), for a liver transplant 14.3 (recipient serum ferritin >500 ug/L), and for a lung transplant 6.3
130 uggestive of hereditary iron deficiency with serum ferritin higher than expected for IDA, mutations i
131 ations of hair zinc in 41.6% of subjects and serum ferritin in 50% were consistent with the presence
132 cardiac and liver T2* magnetic resonance and serum ferritin in 652 thalassemia major patients from 21
135 investigate differences in concentrations of serum ferritin in patients with and without periodontal
136 also a significantly greater improvement in serum ferritin in the combined group (-976 versus -233 m
138 ans (low bone mineral density [BMD], 23.2%), serum ferritin (iron overload, 24.0%), and pulmonary fun
140 oderately high levels of three iron markers (serum ferritin, iron, and iron saturation ratio) or admi
145 , reticulocyte hemoglobin equivalent >25 pg, serum ferritin level >15 ng/mL, and total iron-binding c
146 the presence of at least 2 of the following: serum ferritin level <12 ng/mL, serum TS level <15%, and
147 ficiency anemia (hemoglobin level <=11 g/dL; serum ferritin level <=100 ng/mL) and intolerance or unr
148 (TS) level (>45%, >50%, and >60%), elevated serum ferritin level (>300, >400, >500, and >600 ng/mL),
149 .026), metastatic disease (P<.001), elevated serum ferritin level (P<.001), unfavorable histopatholog
150 significant correlation was observed between serum ferritin level and cardiac T2* MRI (p = 0.68, r =
151 425 mug/dL at the 12-week visit), changes in serum ferritin level and total iron-binding capacity, ad
156 serum ferritin level of 15 to 100 ng/mL or a serum ferritin level of 101 to 299 ng/mL with transferri
157 rEF (<40%) and iron deficiency, defined as a serum ferritin level of 15 to 100 ng/mL or a serum ferri
158 , the post-treatment degree of change in the serum ferritin level was positively and significantly as
161 on level, serum transferrin-iron saturation, serum ferritin level, and hepatic iron index (P < 0.05).
164 2Y homozygotes and 1,367 nonhomozygotes with serum ferritin levels >300 mug/L in men and >200 mug/L i
166 nd hepatic outcomes of 1-year maintenance of serum ferritin levels <50 mug/L by bloodletting associat
168 th transferrin saturation > 50%; p = 0.003), serum ferritin levels (77.8% versus 33.3% with serum fer
169 lori infection was associated with decreased serum ferritin levels (percent change = -13.9%, 95% conf
171 it during the neonatal period, and increased serum ferritin levels and a lower incidence of iron-defi
172 significant correlation was observed between serum ferritin levels and the number of sites with PD >/
177 quares mean difference between the groups in serum ferritin levels at week 48 was -348 mug per liter
178 tin doses, and available surrogates of MICS, serum ferritin levels between 200 and 1200 ng/ml (refere
179 r receiving deferasirox for 48 weeks, median serum ferritin levels decreased by 63.5%, 74.8%, and 74.
180 rrhosis compared with 39 of 89 patients with serum ferritin levels greater than 1000 microg/L (P < 0.
181 erum aminotransferase levels (P = 0.001) and serum ferritin levels greater than 1000 microg/L (P = 0.
182 crog/L compared with 72% among patients with serum ferritin levels greater than 1000 microg/L after a
185 ty of cirrhosis was 7.4% among patients with serum ferritin levels less than 1000 microg/L compared w
186 es or C282Y/H63D compound heterozygotes with serum ferritin levels less than 1000 microg/L had cirrho
187 ong periods of time, excluding subjects with serum ferritin levels less than or equal to 1000 microg/
189 ps/Kaiser hemochromatosis study, only 59 had serum ferritin levels more than 1000 microg/L; 24 had ho
190 were homozygous for the Cys282Tyr mutation, serum ferritin levels of 300-2000 ng/mL, transferrin sat
192 erapy can produce hematologic responses with serum ferritin levels up to 400 microg/L, indicating tha
200 ber, Shimada histopathologic classification, serum ferritin levels, and bone marrow immunocytology we
201 Hepcidin excretion correlated well with serum ferritin levels, which are regulated by similar pa
206 s model of assessment of insulin resistance, serum ferritin, lipid profile, and liver function tests
207 )-labelled ferrous sulfate in iron-depleted (serum ferritin </=25 mug/L) women aged 18-40 years recru
208 between infants with latent iron deficiency (serum ferritin </=75 ng/mL) and infants with normal iron
210 iron deficiency (ID) by the iron indicators serum ferritin <15 ug/L, serum soluble transferrin recep
211 s who took iron supplements, even those with serum ferritin <21 microg/L (n = 5), adapted to absorb l
212 hemotherapy-related anemia (Hb <or= 105 g/L, serum ferritin <or= 450 pmol/L or <or= 675 pmol/L with t
213 al values for iron measures were as follows: serum ferritin <or=8.7 or <10.0 microg/L, serum transfer
215 For example, the analytic variability of serum ferritin measurements across laboratories is very
216 lar ejection fraction (LVEF) of 56% or more, serum ferritin more than 2500 ng/mL, liver iron concentr
220 were observed, whereas time had an effect on serum ferritin (P < or = 0.0001) and hemoglobin (P = 0.0
221 = 0.05) and were positively associated with serum ferritin (P < or = 0.05) and C-reactive protein (P
222 roup were associated with greater changes in serum ferritin (P = 0.01) and body iron (P = 0.01), but
225 ors [blood lipids, oxidative stress indexes, serum ferritin, plasma folate, plasma vitamin B-12, and
226 s on admission: elevated C-reactive protein, serum ferritin, procalcitonin, N-terminal pro B-type nat
228 on absorption was negatively correlated with serum ferritin (r = -0.59, P < 0.001) and with plasma he
229 Serum hepcidin appropriately correlated with serum ferritin (r = 0.63), reflecting the regulation of
231 Serum prohepcidin correlated directly with serum ferritin (R2 = 0.28, P < 0.01) but was unrelated t
233 condition is typically characterized by high serum ferritin, reduced transferrin saturation, and macr
234 pients (n=169), increased baseline levels of serum ferritin reliably predicted a positive outcome for
236 ty in TAS was accounted for by baseline TAS, serum ferritin, serum estrone, dietary zinc, and dietary
239 ence interval [CI]: 0.03-0.71) together with serum ferritin, serum transferrin, transferrin saturatio
240 of TfR1 was related to midgestation maternal serum ferritin (SF) (beta = -0.32; P = 0.005) and serum
241 ncentrations on estimates of ID according to serum ferritin (SF) (used generically to include plasma
242 ondary outcomes were change from baseline in serum ferritin (SF) and 25-hydroxyvitamin D [25(OH)D], r
243 between race-ethnicity-specific quartiles of serum ferritin (SF) and a set of CVD risk factors [body
249 of iron deficiency (ID) but also have higher serum ferritin (SF) concentrations than those of the gen
250 f reproductive age, median or geometric mean serum ferritin (SF) concentrations were estimated at 26-
253 onship between mobilized iron (mob Fe), age, serum ferritin (SF), and quantitative hepatic iron (QHI)
254 nd urinary hepcidin and their relations with serum ferritin (SF), serum transferrin receptor (sTfR),
255 wk; n = 61) were used to assess hemoglobin, serum ferritin (SF), soluble transferrin receptor (sTfR)
256 trials that assessed effects on hemoglobin, serum ferritin (SF), soluble transferrin receptor, or bo
257 us relies on serum-based indicators, such as serum ferritin (SF), transferrin saturation, and soluble
260 mo of age; 2) hemoglobin, hematocrit, iron [serum ferritin (SF)], and zinc status at 12 mo of age; a
261 -two iron-depleted, nonanemic Chinese women [serum ferritin (sFer) <25 mug/L and hemoglobin >110 g/L]
262 cans with elevated saturated transferrin and serum ferritin show higher prevalence of the P47S varian
266 n were assigned to two groups, stratified by serum ferritin so that two groups with similar iron stat
267 hropometry; nutritional biomarkers including serum ferritin, soluble transferrin receptor, retinol-bi
270 ents with CP showed higher concentrations of serum ferritin than periodontally healthy controls (P <0
272 n be derived for any target concentration of serum ferritin, thereby giving risk managers and public
275 ping and association studies for serum iron, serum ferritin, transferrin saturation (SAT) and total i
276 ategy controlled study-wise type 1 error for serum ferritin, transferrin saturation, and intravenous
277 d in blood indexes of iron status (including serum ferritin, transferrin saturation, and non-transfer
279 ns should closely monitor renal function and serum ferritin, use the lowest effective dose to maintai
280 values correlated strongly with traditional serum ferritin values (r = 0.88 and 0.86, respectively;
281 +/- 9.4 microg/L higher, respectively, than serum ferritin values obtained with the traditional meth
282 treatment (P <0.01), and the post-treatment serum ferritin values were comparable to those of contro
286 omol/g and 41.6% were < or =1.68 micromol/g; serum ferritin was 25.7 +/- 18.6 microg/L and 50.0% were
287 fter treatment, a significant improvement in serum ferritin was associated with a 5-7-fold improvemen
292 n in all other groups at ages 4 and 5 mo and serum ferritin was lower in the RTF-12 group than in the
299 ll sources was strongly inversely related to serum ferritin, with geometric means of 32.5% (iron asco
300 -d food diary was completed, and hemoglobin, serum ferritin, zinc, copper, and C-reactive protein con